Outcome of patients with advanced-stage NLPHL compared with matched controls with advanced-stage CHL
| . | HL subtype . | Survival (%) . | P . | ||
|---|---|---|---|---|---|
| 5-Year . | 10-Year . | 15-Year . | |||
| HL-FFTF | NLPHL | 82 | 75 | 52 | .610 |
| CHL | 78 | 73 | 73 | ||
| TTP | NLPHL | 72 | 63 | 44 | .040 |
| CHL | 78 | 73 | 73 | ||
| OS | NLPHL | 89 | 83.5 | 74 | .826 |
| CHL | 91 | 81 | 68 | ||
| TTT | NLPHL | 12 | 15 | 24 | .00018 |
| CHL | 0 | 0 | 0 | ||
| . | HL subtype . | Survival (%) . | P . | ||
|---|---|---|---|---|---|
| 5-Year . | 10-Year . | 15-Year . | |||
| HL-FFTF | NLPHL | 82 | 75 | 52 | .610 |
| CHL | 78 | 73 | 73 | ||
| TTP | NLPHL | 72 | 63 | 44 | .040 |
| CHL | 78 | 73 | 73 | ||
| OS | NLPHL | 89 | 83.5 | 74 | .826 |
| CHL | 91 | 81 | 68 | ||
| TTT | NLPHL | 12 | 15 | 24 | .00018 |
| CHL | 0 | 0 | 0 | ||
TTT, time to transformation.